Monoclonal Antibody Treatment
Ascent has been approved to provide monoclonal antibody treatment against Covid-19!
If you have recently tested positive for COVID-19 by an rt-PCR test, you may have a new treatment option: monoclonal antibody infusion. The research suggests that for certain people, taking this drug may help limit the replication (growth) of virus in the body. This could help symptoms improve quicker, reduce the risk of a life-threatening infection, and reduce hospitalizations.
Important facts about Monoclonal Antibody Infusions
This monoclonal antibody treatment is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults who weigh at least 88 pounds [40 kg] and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
It has not been approved but has been authorized for emergency use by FDA.
This treatment is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
What is Monoclonal Antibody Treatment?
When there is a virus in your body, like COVID-19, your immune system makes antibodies to fight it off. It takes time for your body to make antibodies for a new virus — and in the meantime, you could get very sick.
This treatment contains man-made antibodies that are like the antibodies of patients who recovered from COVID-19. Scientists think that these antibodies may help limit the amount of virus in your body. This could give your body more time to learn how to make its own antibodies, and does not have any COVID-19 virus in it.
Who qualifies for this drug?
Monoclonal Antibody Treatment is a treatment option at Ascent for patients aged 18 or older who tested positive for COVID-19 by rt-PCR test, have had mild to moderate symptoms for 10 days or less, and are at high risk to get very sick from COVID-19.
For adults weighing at least 88 pounds [40 kg], this may be an option if you meet any one of the following criteria:
- Are age 65 or older
- Has obesity, with a body mass index (BMI) of 35 or higher
- Has diabetes, chronic kidney disease, or a condition that weakens the immune system
- Take medication that weakens the immune system
- Has sickle cell disease
- Has a developmental condition, like cerebral palsy
- Has asthma or a long-term lung disease that requires daily medication for control
- Regularly uses medical technology, like a ventilator or feeding tube
Adults also qualify for monoclonal antibody treatment if they are age 55 or older AND have at least one of the following:
- Heart disease
- High blood pressure
- Long-term lung disease
This drug is not for people who are already in the hospital because of COVID-19.